OBJECTIVE: To describe imaging features of primary and metastatic alveolar soft part sarcoma (ASPS). METHODS: In this institutional review board-approved and Health Insurance Portability and Accountability Act-compliant retrospective study, 25 patients (14 males; mean age, 25 years; range, 18-40 years) with pathologically proven ASPS seen at our institute between 1995 and 2013 were included. Imaging of primary tumours in 5 patients and follow-up imaging in 25 patients were reviewed by 2 radiologists in consensus. Clinical information was obtained from electronic medical records. RESULTS: The most common sites for the primary tumour were extremities (17/25, 68%) and torso (6/25, 24%). Primary tumours (n = 5) were well circumscribed, compared with skeletal muscle, were isodense on CT, hyperintense on T1 and T2 weighted images with intense post-contrast enhancement, prominent feeders on CT and flow voids on MRI. Metastases developed in 23/25 (92%) patients, 18 at presentation. The most common sites of metastases were the lungs (100%), lymph nodes (74%), bones (57%) and brain (43%). Visceral and nodal metastases were hypervascular. At the time of reporting the results, 15 patients have died, 6 are alive and 4 were lost to follow-up. Median survival was 74 months for those without brain metastases (n = 8) and 60 months for those with brain metastases (n = 7). Median survival was shorter for patients with metastases at presentation. CONCLUSION: ASPS most commonly involves the lower extremities of young adults, is hypervascular on imaging, often metastasizes at presentation, frequently to lung, nodes, bones and brain, and has an indolent course despite metastases. Brain metastases and high tumour burden (number of metastatic sites) at presentation decreased survival in our study. ADVANCES IN KNOWLEDGE: ASPS has an unusual pattern of metastases to the brain and nodes in addition to lung and bones. It has an indolent course despite metastases.
OBJECTIVE: To describe imaging features of primary and metastatic alveolar soft part sarcoma (ASPS). METHODS: In this institutional review board-approved and Health Insurance Portability and Accountability Act-compliant retrospective study, 25 patients (14 males; mean age, 25 years; range, 18-40 years) with pathologically proven ASPS seen at our institute between 1995 and 2013 were included. Imaging of primary tumours in 5 patients and follow-up imaging in 25 patients were reviewed by 2 radiologists in consensus. Clinical information was obtained from electronic medical records. RESULTS: The most common sites for the primary tumour were extremities (17/25, 68%) and torso (6/25, 24%). Primary tumours (n = 5) were well circumscribed, compared with skeletal muscle, were isodense on CT, hyperintense on T1 and T2 weighted images with intense post-contrast enhancement, prominent feeders on CT and flow voids on MRI. Metastases developed in 23/25 (92%) patients, 18 at presentation. The most common sites of metastases were the lungs (100%), lymph nodes (74%), bones (57%) and brain (43%). Visceral and nodal metastases were hypervascular. At the time of reporting the results, 15 patients have died, 6 are alive and 4 were lost to follow-up. Median survival was 74 months for those without brain metastases (n = 8) and 60 months for those with brain metastases (n = 7). Median survival was shorter for patients with metastases at presentation. CONCLUSION:ASPS most commonly involves the lower extremities of young adults, is hypervascular on imaging, often metastasizes at presentation, frequently to lung, nodes, bones and brain, and has an indolent course despite metastases. Brain metastases and high tumour burden (number of metastatic sites) at presentation decreased survival in our study. ADVANCES IN KNOWLEDGE: ASPS has an unusual pattern of metastases to the brain and nodes in addition to lung and bones. It has an indolent course despite metastases.
Authors: J S Suh; J Cho; S H Lee; K H Shin; W I Yang; J H Lee; J H Cho; K J Suh; Y J Lee; K N Ryu Journal: Skeletal Radiol Date: 2000-12 Impact factor: 2.199
Authors: Megan E Anderson; Francis J Hornicek; Mark C Gebhardt; Kevin A Raskin; Henry J Mankin Journal: Clin Orthop Relat Res Date: 2005-09 Impact factor: 4.176
Authors: Marc Ladanyi; Cristina R Antonescu; Marija Drobnjak; Ann Baren; Man Yee Lui; David W Golde; Carlos Cordon-Cardo Journal: Am J Pathol Date: 2002-04 Impact factor: 4.307
Authors: C A Portera ; V Ho; S R Patel; K K Hunt; B W Feig; P M Respondek; A W Yasko; R S Benjamin; R E Pollock; P W Pisters Journal: Cancer Date: 2001-02-01 Impact factor: 6.860
Authors: Soha Riad; Anthony M Griffin; Boaz Liberman; Martin E Blackstein; Charles N Catton; Rita A Kandel; Brian O'Sullivan; Lawrence M White; Robert S Bell; Peter C Ferguson; Jay S Wunder Journal: Clin Orthop Relat Res Date: 2004-09 Impact factor: 4.176
Authors: Sree Harsha Tirumani; Jyothi P Jagannathan; Kevin O'Regan; Kyung Won Kim; Atul B Shinagare; Katherine M Krajewski; Nikhil H Ramaiya Journal: Cancer Imaging Date: 2013-05-02 Impact factor: 3.909
Authors: Matthew D Cykowski; John Hicks; David I Sandberg; Adriana Olar; Julia A Bridge; Patricia T Greipp; Patricia Navarro; Steven Kolodziej; Meenakshi B Bhattacharjee Journal: Ultrastruct Pathol Date: 2014-09-30 Impact factor: 1.094
Authors: A D Baheti; S H Tirumani; R Sewatkar; A B Shinagare; J L Hornick; N H Ramaiya; J P Jagannathan Journal: Br J Radiol Date: 2014-11-28 Impact factor: 3.039